Adjuvant chemotherapy for uterine leiomyosarcoma
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether giving two chemotherapy drugs, doxorubicin and trabectedin, after surgery can lower the chance of uterine leiomyosarcoma coming back. It is for people whose cancer was completely removed but who have a high risk of relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with uterine leiomyosarcoma, a type of cancer in the muscle of the uterus.
- Your cancer was localized (stages 1b to 3) and completely removed by surgery, including a hysterectomy, within the last 3 months.
- You have no signs of cancer remaining after surgery, confirmed by a CT scan of the chest, abdomen, and pelvis within 30 days.
- You have not had radiation to the pelvic area or chemotherapy for this cancer before.
- You are 18 years or older and in generally good health, with adequate organ and bone marrow function.
- You have no significant heart problems, as shown by an LVEF (heart function test) greater than 50%.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether letrozole can help prevent uterine leiomyosarcoma from coming back after surgery. It focuses on people whose tumor shows estrogen receptor positivity.
This trial tests a combination of immunotherapy (atezolizumab), chemotherapy (doxorubicin), and radiation before and after surgery for people with high-risk soft tissue sarcoma in the arm, leg, or trunk. The goal is to see if this approach can improve outcomes.
This trial tests whether chemotherapy after surgery can help prevent uterine leiomyosarcoma from coming back in patients who are at high risk based on a genetic test of their tumor. It is for women with early-stage cancer (stage I) who have had complete surgery.
This Phase 2 trial studies how well gemcitabine or trabectedin works for people with leiomyosarcoma that cannot be fully removed or has spread. It’s for tumors that have grown or worsened despite prior standard chemotherapy.
This Phase 2 study tests a combination of three anti-cancer medicines to shrink or control leiomyosarcoma that cannot be fully removed by surgery or has spread. It may help people whose cancer has grown after prior treatment.
This study tests a combination of two chemotherapy drugs—utidelone and doxorubicin—for people with advanced soft tissue sarcoma. The goal is to see if this combination can help shrink or slow the cancer.
Hear when a new Uterine Leiomyosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.